Asimadoline in the treatment of irritable bowel syndrome

Bibliography

• Lembo AJ. The clinical and economic burden of irritable bowel syndrome. Pract Gastroenterol 2007;31(Suppl):3-9
   Google Scholar
• Mayer EA. Irritable bowel syndrome. N Eng J Med 2008;358:1692-9
   PubMed Web of Science ®Google Scholar
• Drossman DA. Rome III. The functional gastrointestinal disorders. In: McLean VA, editor, Degnon Associates, Inc.; 2006
   Google Scholar
• Drossman DA, Whitehead WE, Camilleri M. Irritable bowel syndrome: a technical review for practice guidelines. Gastroenterology 1997;112:2120-37
   PubMed Web of Science ®Google Scholar
• Camilleri M. Mechanisms in IBS: something old, something new, something borrowed…. Neurogastroenterol Motil 2005;17:311-16
   PubMed Web of Science ®Google Scholar
• Drossman DA, Li Z, Andruzzi E, US householder survey of functional gastrointestinal disorders: prevalence, sociodemography, and health impact. Dig Dis Sci 1993;38:1569-80
   PubMed Web of Science ®Google Scholar
• Sandler RS. Epidemiology of irritable bowel syndrome in the United States. Gastroenterology 1990;99:409-15
   PubMed Web of Science ®Google Scholar
• Thompson WG, Irving EJ, Pare P, Functional gastrointestinal disorders in Canada: first population-based survey using Rome II criteria with suggestions for improving the questionnaire. Dig Dis Sci 2002;47:225-35
   PubMed Web of Science ®Google Scholar
• Ruigomez A, Wallander MA, Johansson S, One-year follow-up of newly diagnosed irritable bowel syndrome participants. Aliment Pharmacol Ther 1999;13:1097-102
   PubMed Web of Science ®Google Scholar
• Andrews EB, Eaton SC, Hollis KA, Prevalence and demographics of irritable bowel syndrome: results from a large web-based survey. Aliment Pharmacol Ther 2005;22:935-42
   PubMed Web of Science ®Google Scholar
• Gralnek IM, Hays RD, Kilbourne A, The impact of irritable bowel syndrome on health-related quality of life. Gastroenterology 2000;119:654-60
   PubMed Web of Science ®Google Scholar
• Watson ME, Lacy L, Kong S, Alosetron improves quality of life in women with diarrhea predominant irritable bowel syndrome. Am J Gastroenterol 2001;96:455-9
   PubMed Web of Science ®Google Scholar
• Patel RP, Pettita A, Fogel R, The economic impact of irritable bowel syndrome in a managed care setting. J Clin Gastroenterol 2002;35:14-20
   PubMed Web of Science ®Google Scholar
• Levy RL, Von Korff M, Whitehead WE, Costs of care for irritable bowel syndrome patients in a health maintenance organization. Am J Gastroenterol 2001;96:3122-9
   PubMed Web of Science ®Google Scholar
• Whitehead WE, Burnett CK, Cook EW, Impact of irritable bowel syndrome on quality of life. Dig Dis Sci 1996;41:2248-53
   PubMed Web of Science ®Google Scholar
• Hahn BA, Yan S, Strassels S. Impact of irritable bowel syndrome on quality of life and resource use in the United States and United Kingdom. Digestion 1999;60:77-81
   PubMed Web of Science ®Google Scholar
• Patrick DL, Drossman DA, Frederick IO, Quality of life in persons with irritable bowel syndrome: development and validation of a new measure. Dig Dis Sci 1998;43:400-11
   PubMed Web of Science ®Google Scholar
• Koloski N, Talley NJ, Boyce PM. The impact of functional gastrointestinal disorders on quality of life. Am J Gastroenterol 2000;95:67-71
   PubMed Web of Science ®Google Scholar
• Irving EJ, Ferrazzi S, Pare P, Health-related quality of life in functional GI disorders: focus on constipation and resource utilization. Am J Gastroenterol 2002;97:1986-93
   PubMed Web of Science ®Google Scholar
• Wells NEJ, Hahn BA, Whorwell PJ. Clinical economics review: irritable bowel syndrome. Aliment Pharmacol Ther 1997;11:1019-30
   PubMed Web of Science ®Google Scholar
• Talley NJ, Gabriel SE, Harmsen WS, Medical costs in community subjects with irritable bowel syndrome. Gastroenterology 1995;109:1736-41
   PubMed Web of Science ®Google Scholar
• Hungin P, Barghout V, Kahler K. The impact of IBS on absenteeism and work productivity: United States and eight European countries. Am J Gastroenterol 2003;98(Suppl):S227
   PubMed Web of Science ®Google Scholar
• Everhart JE, Renault PF. Irritable bowel syndrome in office-based practice in the United States. Gastroenterology 1991;100:998-1005
   PubMed Web of Science ®Google Scholar
• Camilleri M, Mayer EA, Drossman DA, Improvement in pain and bowel function in female irritable bowel patients with alosetron, a 5HT3 receptor antagonist. Aliment Pharmacol Ther 1999;13:1149-59
   PubMed Web of Science ®Google Scholar
• Mangel AW, Northcutt AR. Review article: safety and efficacy of alosetron, a 5HT3 receptor antagonist, in female irritable bowel syndrome patients. Aliment Pharmacol Ther 1999;13(Suppl 2):77-82
   PubMed Web of Science ®Google Scholar
• Camilleri M, Northcutt AR, Kong S, The efficacy and safety of alosetron in female patients with irritable bowel syndrome: a randomized, placebo controlled trial. Lancet 2000;335:1035-40
   Web of Science ®Google Scholar
• Camilleri M, Chey WY, Mayer EA, Alosetron relieves abdominal pain, and improves abnormal bowel function in female, non-constipated, irritable bowel syndrome patients. Arch Intern Med 2001;161:1733-40
   PubMed Web of Science ®Google Scholar
• Tack J, Muller-Lissner S, Bytzer P, A randomized controlled trial assessing the efficacy and safety of repeated tegaserod therapy in women with irritable bowel syndrome with constipation. Gut 2005;54:1707-13
   PubMed Web of Science ®Google Scholar
• Kellow J, Lee OY, Chang FY, An Asia-Pacific, double blind, placebo controlled, randomized study to evaluate the efficacy, safety, and tolerability of tegaserod in patients with irritable bowel syndrome. Gut 2003;52:671-6
   PubMed Web of Science ®Google Scholar
• Drossman DA, Chey WD, Johanson JF, Clinical trial: lubiprostone in patients with constipation-associated irritable bowel syndrome—results of two randomized, placebo-controlled studies. Aliment Pharmacol Ther 2009;29:329-41
   PubMed Web of Science ®Google Scholar
• Camilleri M. Asimadoline, a kappa-opioid agonist, and visceral sensation. Neurogastroenterol Motil 2008;20:971-9
   PubMed Web of Science ®Google Scholar
• Mangel AW, Bornstein JD, Hamm LR, Clinical trial: asimadoline in the treatment of patients with irritable bowel syndrome. Aliment Pharmacol Ther 2008;28:239-49
   PubMed Web of Science ®Google Scholar
• Pimentel M, Lembo A, Chey WD, Rifaximin treatment for 2 weeks provides acute and sustained relief over 12 weeks of IBS symptoms in non-constipated irritable bowel syndrome: results from 2 North American phase 3 trials (Target 1 and Target 2). American Gastroenterology Abstracts; New Orleans, LA, USA; 2010. p. #475i
   Google Scholar
• Leventer SM, Raudibaugh K, Frissora CL, Clinical trial: dextofisopam in the treatment of patients with diarrhoea-predominant or alternating irritable bowel syndrome. Aliment Pharmacol Ther 2008;27:197-206
   PubMed Web of Science ®Google Scholar
• Mangel AW, Chaturvedi P. Evaluation of crofelemer in the treatment of diarrhea-predominant irritable bowel syndrome patients. Digestion 2008;78:180-6
   PubMed Web of Science ®Google Scholar
• Tack JF, Harris MS, Proksch S, AST-120 (Spherical Carbon Adsorbent) improves pain and bloating in a randomized, double-blind, placebo-controlled trial in patients with non-constipating irritable bowel syndrome (IBS). American Gastroenterology Abstracts; New Orleans, LA, USA; 2010. p. S1298
   Google Scholar
• Asimadoline Investigators Brochure. Version 8. Tioga Pharmaceuticals, 2010
   Google Scholar
• Burton MB, Gebhart GF. Effects of kappa-opioid receptor agonists on responses to colorectal distension in rats with and without acute colonic inflammation. J Pharmacol Exp Ther 1998;285:707-15
   PubMed Web of Science ®Google Scholar
• Larsson M, Arvidsson S, Ekmani C, A model for chronic quantitative studies of colorectal sensitivity using balloon distension in conscious mice-effects of opioid receptor agonists. Neurogastroenterol Motil 2003;15:371-81
   PubMed Web of Science ®Google Scholar
• Delgado-Aros S, Chial HJ, Camilleri M, Effects of a kappa-opioid agonist, asimadoline, on satiation and GI motor and sensory functions in humans. Am J Physiol 2003;284:G558-66
   PubMed Web of Science ®Google Scholar
• Delvaux M, Beck A, Jacob J, Effect of asimadoline, a kappa opioid agonist, on pain induced by colonic distension in patients with irritable bowel syndrome. Aliment Pharmacol Ther 2004;20:237-46
   PubMed Web of Science ®Google Scholar
• Szarka LA, Camilleri M, Burton D, Efficacy of on-demand asimadoline, a peripheral k-opioid agonist, in females with irritable bowel syndrome. Clin Gastroenterol Hepatol 2007;5:1268-75
   PubMed Web of Science ®Google Scholar
• Guidance for industry: irritable bowel syndrome-clinical evaluation of products for treatment: United States Food and Drug Administration; Rockville, Maryland, USA; 2010
   Google Scholar
• Kramer HJ, Uhl W, Ladstetter B, Influence of asimadoline, a new k-opioid receptor agonist, on tubular water absorption and vasopressin secretion in man. Br J Clin Pharmacol 2000;50:227-35
   PubMed Web of Science ®Google Scholar